Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otelixizumab for early or new-onset type 1 diabetes
NL-OMON34462Phase 3Withdrawn
- Sponsor
- Tolerx, Inc.
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Otelixizumab with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Planned start Jun 2010; status: withdrawn.
02
Drugs
otelixizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON34462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34462.